on BioNxt Solutions Inc. (isin : CA0909741062)
BioNxt Explores New Delivery Method for Semaglutide with Feasibility Study
BioNxt Solutions Inc. has announced a feasibility study to develop an oral dissolvable film (ODF) version of Semaglutide, a GLP-1 receptor agonist. This marks an exploration into BioNxt's drug delivery platform as an alternative to current injectable and tablet forms of Semaglutide, known by brands like Ozempic®, Rybelsus®, and Wegovy®.
The study will test compatibility between Semaglutide and BioNxt's ODF technology, aiming to gather data for formulation improvement and intellectual property strategies. CEO Hugh Rogers emphasized the potential to improve patient adherence with a non-invasive delivery option.
Semaglutide has gained traction for conditions like type 2 diabetes and obesity. Despite market success, current formulations are cumbersome, requiring injections or large tablets. A dissolvable thin film could enhance convenience and patient experience.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BioNxt Solutions Inc. news